GSK2606414 administration reduced tau phosphorylation, mitigated brain atrophy, and improved clinical signs by decreasing the p-eIF2α/eIF2α ratio and restoring global translation rates [98]. This evidence concerns the gene EIF2A and Brain atrophy.